Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 798 results for "mg johnson"

Amgen, AstraZeneca Report Phase 3 Brodalumab Meets Endpoints In Psoriasis
Bioresearch Online

Amgen (AMGN), AstraZeneca PLC (AZN)'s Brodalumab Phase 3 Study...

November 26, 2014 By Jessica Wilson , Breaking News Staff Amgen ( AMGN ) and AstraZeneca ( AZN ) today announced the results of another Phase III trial, this one named AMAGINE-2, which showed, once again, that the drug brodalumab ... ClinicSpace, 2 days ago
Recognizing potential in RSV Drug Discovery News, 2 weeks ago

1 images for "mg johnson"

Exhibit City News, 1 week ago

Pakistan vs Australia 1st Test: Pak 219-4 in 90 overs

Younis Khan lbw b Johnson 106 (223b 10x4 1x6) Azhar Ali c Doolan b Johnson 53 (167b 6x4 0x6) Pakistan are in dire straits having lost both openers Hafeez and Shehzad cheaply. OUT! Siddle strikes castling Shehzad who attempts to clip him to ...
 Emirates2471 month ago 2nd Test: Pakistan elect to bat vs Australia  SAMAA TV4 weeks ago 1st Test: Pakistan opt to bat vs Australia  SAMAA TV1 month ago Doolan hits hundred as Clarke fails in warm-up  The Nation Pakistan1 month ago

Mayor of London heads to Far East to boost trade and investment for capital

The Mayor of London, Boris Johnson, will build on his work to create jobs and growth, and promote London to the world as a major investment destination as he leads a trade mission to Singapore, Jakarta and Kuala Lumpur this week. The Mayor will ... days ago Skills London 2014 week ago
Exhibit City News

MG Design Builds New Business Development Team

MG Design is pleased to welcome Jacqueline Johnson, Wade Kerscher and Jodi Potirala to the New Business Development Team reporting to New Business Development Manager Dale Beyer. Jacqueline Johnson is a Business Development Associate in Pleasant ...
 Exhibitor Online1 week ago MG Design expands new business development team  Exhibit City News1 week ago

Johnson & Johnson : Janssen Submits Application Seeking Approval Of SIMPONI® In European Union For Non-Radiographic Axial Spondyloarthritis

― Janssen Biologics B.V. (Janssen) announced today that a Type II Variation has been filed with the European Medicines Agency seeking approval of SIMPONI® (golimumab) for the treatment of severe active non-radiographic axial spondyloarthritis ...
 4 Traders1 week ago Janssen Submits Application Seeking Approval of SIMPONI® in European Union for Non-Radiographic Axial Spondyloarthritis  Biotechgate1 week ago

Magnesium Sulfate Treatment Reverses Seizure Susceptibility and Decreases Neuroinflammation in a Rat Model of Severe Preeclampsia

by Abbie Chapman Johnson, Sarah M. Tremble, Siu-Lung Chan, Janae Moseley, Babbette LaMarca, Keith J. Nagle, Marilyn J. Cipolla Eclampsia, defined as unexplained seizure in a woman with preeclampsia, is a life-threatening complication of pregnancy ...
 Plosone.org1 week ago

Mallinckrodt Pharmaceuticals (MNK)'s Generic ADHD Drug Does Not Measure Up To Johnson & Johnson (JNJ)'s Concerta: FDA 11/14/2014

Mallinckrodt plc Responds to FDA's Expected Reclassification of Methylphenidate ER DUBLIN, Nov 13, 2014 (BUSINESS WIRE) -- Mallinckrodt has been informed by the U.S. Food and Drug Administration (FDA) that the agency has reason to believe that ...
 ClinicSpace2 weeks ago Mallinckrodt Pharmaceuticals's Generic ADHD Drug Does Not Measure Up To Johnson & Johnson's Concerta: FDA  BioSpace2 weeks ago Mallinckrodt questions FDA reasoning on methylphenidate ER reclassification  Pharma Letter2 weeks ago

JOHNSON & JOHNSON : Janssen to Demonstrate Breadth of Oncology Portfolio with 41 Clinical Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting

Note: This release corresponds to ASH abstracts 22, 31, 78, 84, 176, 327, 505, 2096, 2312, 3448, 3474, 4469, 4680 RARITAN, NJ, November 6, 2014 - Janssen Research & Development, LLC (Janssen) will present new data across more than eight ...
 4 Traders3 weeks ago Janssen to Demonstrate Breadth of Oncology -3-  Scottrade3 weeks ago Janssen Research & Development To Demonstrate Breadth Of Oncology Portfolio With 42 Clinical Data Presentations At The 2014 American Society of Hematology Annual Meeting  BioSpace3 weeks ago

Janssen's Olysio/sofosbuvir combination cleared by FDA

The Food and Drug Administration has approved US health care giant Johnson & Johnson's (NYSE: JNJ) Olysio (simeprevir) in combination with sofosbuvir (Gilead Sciences new blockbuster hepatitis C drug Sovaldi) as an all-oral, interferon- and ...
 Pharma Letter3 weeks ago Johnson & Johnson (JNJ), Medivir AB (MVRBF) Snags U.S. Approval For Hepatitis C Combo With Gilead Sciences, Inc. (GILD) 11/6/2014  ClinicSpace3 weeks ago Johnson & Johnson, Medivir AB Snags U.S. Approval For Hepatitis C Combo With Gilead Sciences, Inc.  BioSpace3 weeks ago OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C  WorldNetDaily3 weeks ago
Surgical Products

Sedasys announces launch of new sedation system in the U.S.

Five bladder cancer experts to receive $250,000 research grants from Johns Hopkins Imperial researchers plan to test DTP3 drug in multiple myeloma patients Group Health's HMO Medicare Advantage plan earns 5-Star rating from CMS Johnson & ...
 News-Medical.Net1 month ago Sedasys Launches Computer-Assisted Personalized Sedation System  Surgical Products1 month ago US Launch Of SEDASYS® System Commences  PR Newswire1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less